These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21854303)

  • 41. Immunoprophylaxis of infections with human cytomegalovirus in BMT patients.
    Mach M; Landini MP
    Bone Marrow Transplant; 1993; 11 Suppl 1():95-6. PubMed ID: 8383558
    [No Abstract]   [Full Text] [Related]  

  • 42. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
    Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The launching of a cytomegalovirus vaccine.
    Hanshaw JB
    Am J Dis Child; 1982 Apr; 136(4):291-2. PubMed ID: 6280489
    [No Abstract]   [Full Text] [Related]  

  • 44. [Vaccines against cytomegalovirus infect. Perspectives].
    Cadoz M; Méric C
    Arch Pediatr; 1999; 6 Suppl 3():655s-658s. PubMed ID: 10429809
    [No Abstract]   [Full Text] [Related]  

  • 45. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire.
    Nastke MD; Herrgen L; Walter S; Wernet D; Rammensee HG; Stevanović S
    Cell Mol Life Sci; 2005 Jan; 62(1):77-86. PubMed ID: 15619009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytomegalovirus infection in patients with solid-organ transplant. Recently reviewed immunologic response and pathogenicity mechanisms.
    Caltenco-Serrano R; Sánchez-Huerta JL; Vargas-Jiménez R; Rodríguez-Suárez RS; Gómez-Barreto D
    Rev Latinoam Microbiol; 2001; 43(4):177-82. PubMed ID: 17061506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reanalysis of TransVax immunogenicity.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2013 Jan; 13(1):18. PubMed ID: 23257230
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169.
    Neff BJ; Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Jan; 160(1):32-7. PubMed ID: 217022
    [No Abstract]   [Full Text] [Related]  

  • 50. Cytomegalovirus vaccine in renal transplants.
    Betts RF
    Ann Intern Med; 1979 Nov; 91(5):780-2. PubMed ID: 227302
    [No Abstract]   [Full Text] [Related]  

  • 51. Vaccination of pediatric nurses with live attenuated cytomegalovirus.
    Fleisher GR; Starr SE; Friedman HM; Plotkin SA
    Am J Dis Child; 1982 Apr; 136(4):294-6. PubMed ID: 6280490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.
    Hudson JB
    Arch Virol; 1979; 62(1):1-29. PubMed ID: 231945
    [No Abstract]   [Full Text] [Related]  

  • 53. Letter: Vaccination against cytomegalovirus?
    Pagano JS; Huang ES
    Lancet; 1974 Feb; 1(7852):316-7. PubMed ID: 4130502
    [No Abstract]   [Full Text] [Related]  

  • 54. Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus.
    Plotkin SA; Weibel RE; Alpert G; Starr SE; Friedman HM; Preblud SR; Hoxie J
    J Infect Dis; 1985 Apr; 151(4):737-9. PubMed ID: 2982973
    [No Abstract]   [Full Text] [Related]  

  • 55. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.
    Elek SD; Stern H
    Lancet; 1974 Jan; 1(7845):1-5. PubMed ID: 4128996
    [No Abstract]   [Full Text] [Related]  

  • 56. Progress in vaccine development for prevention of human cytomegalovirus infection.
    Gönczöl E; Plotkin S
    Curr Top Microbiol Immunol; 1990; 154():255-74. PubMed ID: 2161323
    [No Abstract]   [Full Text] [Related]  

  • 57. Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives.
    Osborn JE
    J Infect Dis; 1981 Apr; 143(4):618-30. PubMed ID: 6263985
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus.
    Howard RJ; Balfour HH
    Proc Soc Exp Biol Med; 1977 Nov; 156(2):365-8. PubMed ID: 200952
    [No Abstract]   [Full Text] [Related]  

  • 59. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevention of cytomegalovirus disease. Report of a conference.
    Plotkin S
    Pediatr Infect Dis; 1984; 3(1):1-4. PubMed ID: 6322140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.